How precision oncology reveals actionable weaknesses in hard-to-treat tumors
-
About Us
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.
-
Our Science
Targeting hidden tumor vulnerabilities through synthetic lethality, metabolic and epigenetic dependencies, and precision oncology approaches designed to overcome tumor growth and drug resistance.
-
PKC Inhibition in UM
Target the main oncogenic driver of uveal melanoma
-
ADC+DDR
Improve efficacy and durability of TOP1 ADCs
-
MTAP Pathway
Exploit a metabolic vulnerability in MTAP-deleted cancers
-
KAT6/7 Inhibition
Simultaneously target key epigenetic drivers of cancer
-
-
Pipeline
Advancing precision oncology therapies and rational combinations designed to target the core vulnerabilities and drivers of molecularly defined cancers.
-
Clinical Trials
Focused on patients with limited treatment options, our trials use precision medicine and predictive biomarkers to accelerate the development of targeted therapies.